New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
11:12 EDTJAZZJazz Pharmaceuticals price target lowered to $151 from $182 at Cantor
Cantor believes an overhang remains on Jazz Pharmaceuticals as the company continues to dispute the wording in the final REMS for Xyrem and the firm now sees a lower chance that the company may be taken over in the next year. Cantor lowered its price target on Jazz to $151 from $182 and maintains its Hold rating on the shares.
News For JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2015
14:42 EDTJAZZJazz Pharmaceuticals management to meet with Canaccord
Group dinner to be held in New York on November 30 hosted by Canaccord.
07:33 EDTJAZZMylan launches Clozapine Orally Disintegrating Tablets in the U.S.
Mylan (MYL) announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo (JAZZ). Mylan received final approval from the FDA for its Abbreviated New Drug Application, or ANDA, for this product, which is used for the treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment.
November 18, 2015
08:28 EDTJAZZLeerink to hold a bus tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use